Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular basis for cholesterol therapy.

C E Rackley1

  • 1Lipid Disorder Center, Division of Cardiology, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, USA.

Cardiology in Review
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering.

The American journal of geriatric cardiology·2001
Same author

Consequences of estrogen deprivation and the rationale for hormone replacement therapy.

The American journal of managed care·2001
Same author

Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.

Postgraduate medicine·1996
Same author

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.

Clinical cardiology·1996
Same author

Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis.

American heart journal·1996
Same author

Estrogen and coronary artery disease in postmenopausal women.

The American journal of medicine·1995
Same journal

Immunometabolism in Cardiovascular Disease: Linking Metabolic Reprogramming to Inflammation, Atherothrombosis, and Clinical Outcomes.

Cardiology in review·2026
Same journal

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same journal

Celiac Disease and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Challenges.

Cardiology in review·2026
Same journal

Valve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
Same journal

Growing Heart Valves in Congenital Cardiac Surgery: Mechanisms and Considerations for Tissue-Engineered Heart Valves, Noncryopreserved Homografts, and Partial Heart Transplantation.

Cardiology in review·2026
Same journal

Implementation Gaps and Limitations of Statin Therapy in Young Adults: Bridging Guideline Recommendations and Real-World Practice.

Cardiology in review·2026
See all related articles

Cholesterol treatment, particularly statin drugs, effectively reduces cardiovascular events by lowering low-density lipoprotein cholesterol. This approach offers a paradigm shift in managing atherosclerotic vascular disease, impacting plaque stabilization and overall cardiovascular health.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Cardiovascular disease management traditionally focused on stenosis and occlusion.
  • Cholesterol treatment success suggests a new paradigm for coronary artery disease.
  • Risk factors for coronary artery disease guide low-density lipoprotein cholesterol reduction goals.

Purpose of the Study:

  • To highlight the role of cholesterol management in cardiovascular disease.
  • To discuss the mechanisms by which cholesterol impacts atherosclerosis.
  • To present a clinical approach to cholesterol-lowering therapy.

Main Methods:

  • Review of clinical trials on cholesterol-lowering drugs, primarily statins.
  • Analysis of National Cholesterol Education Program guidelines.

Related Experiment Videos

  • Examination of effects on hepatic cholesterol metabolism, vascular reactivity, and inflammation.

    • Main Results:

    • Statin drugs reduce cardiovascular events in men and women, even without prior disease.
    • Cholesterol lowering demonstrates angiographic stabilization.
    • Benefits include reduced cardiovascular events, revascularization, and strokes.
    • Emerging evidence supports triglyceride lowering and HDL cholesterol raising.

    Conclusions:

    • Cholesterol therapy is crucial for managing atherosclerotic vascular disease.
    • Statins offer broad benefits beyond lipid reduction, including plaque stabilization.
    • A clinical strategy using available drugs is presented for comprehensive patient care.